Le Lézard
Classified in: Health
Subject: ACC

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm


UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds").

Pursuant to the terms and conditions for the Bonds, Orexo has undertaken to apply for admission to trading of the Bonds on the sustainable bond list of Nasdaq Stockholm. For this purpose, the Company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the Company's website www.orexo.com and at the Swedish Financial Supervisory Authority's website www.fi.se. The application for admission to trading has been submitted and the first day of trading of the Bonds is estimated to be around May 14, 2024.

For further information please contact:
Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: [email protected]

About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on May 10, 2024, at 1.30 pm CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm,c3976889

The following files are available for download:

https://mb.cision.com/Main/694/3976889/2788792.pdf

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

 

SOURCE Orexo


These press releases may also interest you

at 05:23
ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...

at 05:00
Specialty Enzymes Market worth $9.2 billion by 2029 - Exclusive Report by MarketsandMarketstm
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...

at 05:00
Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...

at 04:37
Cytotoxic Drugs and HPAPI Manufacturing Market worth USD 27.1 Billion to 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing  Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...

at 04:32
Direct Primary Care Market Size to Reach USD 80.4 Billion by 2031- Latest Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC...

at 04:32
High-Growth Industries with 25%-30% CAGR Growth Over the Next Five Years
The Compound Annual Growth Rate (CAGR) measures how much an investment grows each year, on average, over a period. It helps to show the overall trend by smoothing out the ups and downs. Recently, BCC Research predicted that a certain industry would...

More news about Health...


News published on and distributed by: